ASH warns NIH cuts would jeopardize blood disorder care and halt key progress in hematology research.

Heme Today
Heme Today covers the latest news and analyses in bleeding, clotting, red blood cell, and iron disorders for hematologists and oncologists focused on bleeding disorders.
Advertisement
Latest News
Gene therapy is reshaping sickle cell care, raising awareness and advancing treatments beyond the lab.
Reduced-intensity HSCT conditioning with lentiviral gene therapy decreased severe vaso-occlusive events by more than 80%.
An interim analysis of the COMPLETE study found that pegcetacoplan improved indicators of blood health.
The SURPASS ET trial evaluated efficacy and safety of ropeginterferon alfa-2b in second-line ET treatment.
Data were presented at EHA2025 on the novel anti-CD38 monoclonal antibody CM313 for chronic ITP.
Evidence was presented at EHA2025 that the agent improves RBC health and blood flow in patients.
Two cases of patients with SCD and history of delayed hemolytic transfusion reaction were presented at EHA2025.
The analysis was an assessment of 15-year follow-up data from the CLIMB study and was presented at EHA2025.
The study data presented at EHA2025 were from patients who had disease resistant to prior therapy or intolerance to therapy.
Conference Coverage
Advertisement
Expert Interviews on Hematology
Blood Cancer Awareness
A phase II trial calculated a 4-year event-free survival rate of 96% and overall survival rate of 100% from the combination.
Differences were identified between patient racial groups and by urban versus rural populations.
A magnetic resonance imaging study has compared tissue iron levels and biventricular function between the two conditions.